1. Is it Time for a Paradigm Change in HIV Management?

3. The Evolution of HIV Management

4. TEMPRANO Study

5. TEMPRANO Study: Serious Events

6. Test and Treat Strategy

7. When to Treat: Unanswered Questions

8. Communicating With the Patient

9. The Shift to Integrase Inhibitors

10. Increased Risk of Suicidality in Patients Treated With EFV-Containing Regimens

11. Increased Risk of Suicidal Behavior With Use of EFV: Results From the START Trial

12. Use of Integrase Inhibitors Worldwide

13. Integrase Inhibitor Efficacy Data

14. Minimal Drug Interactions With Integrase Inhibitors

15. Tuberculosis and Drug Interactions

16. Is it Beneficial To Use Fewer Agents?

17. PADDLE: Viral Suppression at Week 48 With a 2-Drug Regimen (Dolutegravir/3TC)

18. Dual Therapy

19. ONCEMRK: RAL 1200 mg Once Daily Noninferior to RAL 400 mg Twice Daily at Wk 48

20. Choosing the Optimal Dual Therapy Treatment

21. The Use of Injectables in Dual Therapy

22. LATTE-2: Cabotegravir IM + Rilpivirine IM for Long-Acting Maintenance ART

23. LATTE-2: Efficacy and Safety Through Maintenance Wk 48

24. LATTE-2: Determining Optimal Dose Interval for Future Studies

25. LATTE-2: Acceptability of Injections

26. The Use of Cabotegravir for PrEP

27. HPTN083 Trial

28. Concluding Remarks

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)